Study objective: Acute renal colic is a common presenting complaint to the emergency department. Recently, medical expulsive therapy using ␣-antagonists or calcium channel blockers has been shown to augment stone passage rates of moderately sized, distal, ureteral stones. Herein is a systematic evaluation of the use of medical expulsive therapy to facilitate ureteral stone expulsion.
INTRODUCTION

Background and Importance
The incidence of kidney stones in the general population appears to be increasing, as does the medical cost associated with this disease. 1, 2 The number of primary outpatient visits, emergency department (ED) encounters, and the total estimated annual expenditure for individuals with claims for a diagnosis of urolithiasis have all doubled from 1994 to 2000, which translates into nearly 2 million primary outpatient visits, roughly 600,000 ED encounters, and approximately $2.1 billion in health care-related expenditures. 3 The majority of individuals with urolithiasis have small (Ͻ5 mm) stones, located in the distal ureter, that are able to pass spontaneously. Both stone expulsion and time to expulsion of ureteral stones depend heavily on stone size and location. [4] [5] [6] [7] [8] [9] [10] Urologic intervention is recommended for ureteral stones that persist for more than 2 months.
Association, European Association of Urology, World Congress of Endourology) in the past 7 years were scrutinized for supplementary data. We attempted to electronically contact the primary authors from published scientific abstracts for information about additional study data, including publication of completed analyses.
Selection
The following inclusion criteria were used to select articles for this review: (1) studies were randomized or controlled clinical trials, (2) patients were older that 18 years, (3) patients were clinically and radiographically diagnosed with acute ureteral colic, (4) therapy was begun in the inpatient or outpatient setting, including the ED, or on referral to a urologist, (5) medical expulsive therapy using an ␣-antagonist or calcium channel blocker was compared to a control group, (6) studies included the primary outcome of interest identified for this analysis.
Validity Assessment
Individual trial characteristics, including study design, conduct, data analysis, and interpretation, were reviewed using the revised CONSORT statement. 18 This 22-item checklist systematically analyzes the quality of reporting the results of parallel-group randomized trials. Additionally, quality was assessed using the Jadad scale for each reviewed study. 19 This validated scale ranges from 0 to 5, with a higher score indicative of a study that had adequate randomization, blinding, and follow-up of withdrawals and dropouts.
Data Abstraction
Independently and in duplicate, 2 of the authors abstracted data from selected trials (A.S., A.L.). Information abstracted included the objective, patient population, baseline patient characteristics, cointerventions, and study results. Discrepancies were discussed and resolved by consensus from these 2 authors.
Study Characteristics
We sought to include all potentially relevant trials using either an ␣-antagonist or calcium channel blocker as an adjuvant medical therapy to promote ureteral stone expulsion. We expected some degree of clinical heterogeneity in our results, given the inclusion of trials that used chemically different drugs with similar mechanisms of action (eg, terazosin, doxazosin) and matching drugs that used alternate formulations (eg, nifedipine immediate release, nifedipine sustained release). Similarly, the variable use of concomitant anticholinergic agents, low-dose steroids, and antibiotics was predicted to amplify the degree of expected heterogeneity.
Quantitative Data Synthesis
We calculated a pooled risk ratio (RR) and 95% confidence intervals (CIs) for the effects ␣-blocker and calcium channel blockers on stone expulsion rate by using the random-effects model described by Der Simonian and Laird. 20 This model was selected because it provides a conservative estimate or treatment effect. Heterogeneity was explored through the use of Cochrane Q test for heterogeneity (which follows a 2 distribution), an estimate of between-study variance known as 2 , and an estimate of the amount of variance across studies due to heterogeneity rather than chance, known as I 2 statistic. 21 On the basis of the pooled RR, we calculated the number needed to treat. The 95% CIs for numbers needed to treat were calculated with the Newcombe-Wilson hybrid score method. 22 Publication bias was explored with the use of funnel plots, 23 the Egger regression asymmetry test, 24 and the Begg adjusted rank correlation test. We used Stata version 8.0 (StataCorp, College Station, TX) for all analyses.
We determined a priori that our sensitivity analysis should focus on the impact of poor-quality studies (ie, Jadad score Ͻ3). To assess the effect of individual studies on the summary RR, we did an influence analysis, 25 in which the pooled estimate was recalculated omitting 1 study at a time. Such a sensitivity analysis demonstrates robustness if all point estimates lie between the confidence limits of the overall summary estimate. Prespecified subgroup analysis included separate analysis of studies that included potential confounders (ie, anticholinergic agents, low-dose steroid, antibiotics), and those that used an ␣-antagonist besides tamsulosin.
RESULTS
Trial Flow
The initial MEDLINE search strategy identified 4,443 possible publications about urolithiasis. Electronic and hand searching for additional data revealed an additional 15 potentially relevant publications for inclusion. After application of the initial exclusion criteria to this search, the abstracts from a total of 211 clinical trials were reviewed ( Figure 1 ). Trials involving procedural or surgical stone removal (nϭ122), treatment with fluids, analgesics, or other medications (nϭ34), ureteral imaging techniques (nϭ13), or unrelated conditions were excluded. The full articles of 32 trials were reviewed. At this level, studies were excluded because of inadequate control group [26] [27] [28] [29] or trials involving the study drugs in the setting of shockwave lithotripsy. [30] [31] [32] [33] [34] [35] The remaining 22 articles are included in this analysis.
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Study Characteristics
No articles followed the revised CONSORT statement guidelines for reporting of randomized controlled trials. Jadad scores ranged from 0 to 3 in all clinical trials reviewed, with a median score of 2 for both ␣-antagonist (Table 1 ) and calcium channel blocker trials ( Table 2 ). Absence of double blinding was the most frequent reason for point deduction. Five scientific assembly abstracts were included in the final analysis. 40, 45, 49, 55, 56 We attempted to contact the authors of these 5 abstracts but received no response at the time of article submission.
Tamsulosin was the ␣-antagonist used in 13 of the 16 trials. [36] [37] [38] [39] [41] [42] [43] [44] [45] [46] [47] [48] 51 The results from trials that included other ␣-antagonists (eg, terazosin, 40, 46, 50 doxazosin 46, 49 ) were combined with the results of tamsulosin and were also analyzed independently. Nifedipine was the calcium channel blocker used in all 9 trials. 39, 43, 45, [52] [53] [54] [55] [56] [57] All the trials allowed for pain medications (commonly nonsteroidal anti-inflammatory medications) and encouraged a minimum of 2 L of fluid intake per day.
The median follow-up period from time of enrollment was 4 weeks (range 1 week to 7 weeks) for ␣-antagonist trials. Similarly, patients in the calcium channel blocker trials were evaluated a median of 4 weeks (range 3 weeks to 7 weeks) after enrollment.
In many of the trials, additional medications (eg, low-dose steroid or steroid-like agent, antibiotic, gastroprotective agent, anxiolytic, anticholinergic agent, antiemetic) were prescribed and were equally matched in the treatment group and standard therapy group. In 3 trials, 2 additional interventions (low-dose steroid plus either an antibiotic 53 or gastroprotective agent 39, 54 ) were present in the treatment group but not the standard therapy group. Aescin, an extract from horse chestnut seed, thought to have some steroid-like properties, was used as an adjunctive medication in 3 trials. 36, 41, 47 Additionally, in 5 trials, the standard therapy group received an anticholinergic agent that was postulated to augment stone expulsion. 37, 42, 43, 48, 55 The reported stone expulsion rate from several studies was adjusted to reflect a worst-case scenario principle. 36, 51, 52, 57 In these trials, unexplained dropouts were considered treatment failures. There were insufficient data to adjust the analysis for one trial. Quantitative Data Synthesis ␣-Antagonist. Pooled data included 1,235 patients from 16 clinical trials [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] (Table 3 ). The overall range of stone size was 3 mm to 18 mm, with a mean stone diameter greater than 5 mm in all trials except 2. 38, 48 All studies evaluated stones located in the distal portion of the ureteral tract.
Although minimal heterogeneity existed in the group of ␣-antagonist studies using the Cochrane Q statistic ( 2 ϭ21.32; Pϭ.13) and 2 test ( 2 ϭ.011), the I 2 statistic was 30% (95% CI 0% to 61%), suggesting a mild to moderate amount of acrossstudy variance caused by heterogeneity.
The combined results of all trials using an ␣-antagonist suggest that a benefit in stone expulsion is achieved when combined with standard therapy (RR 1.59; 95% CI 1.44 to 1.75) (Figure 2 ). The number needed to treat is 3.3 (95% CI 2.1 to 4.5). The funnel plot visually demonstrated mild asymmetry ( Figure 3) . However, evidence for publication bias was suggested through analysis by Begg's test (Pϭ.003) and Egger's test (t for biasϭ2.7; Pϭ.02).
Nine trials evaluated time to stone expulsion (Table 3) . In all 9 trials, a 2-to 6-day average improvement in time to stone expulsion was observed in patients receiving an ␣-antagonist compared with the control group. The mean time to stone expulsion in the treatment group, including the upper limit of the 95% CI, was less than 14 days in patients receiving an ␣-antagonist.
Adverse effects were not consistently reported for all the trials. Overall, adverse effects were observed in 4% of patients. Mild adverse effects included dizziness (nϭ6), headache (nϭ4), nausea/vomiting (nϭ2), asthenia (nϭ2), and not recorded (nϭ3). Transient hypotension, not requiring discontinuation of therapy, occurred in 8 patients. One patient experienced severe asthenia and discontinued therapy (0.2%).
Calcium channel blocker. Pooled data included 686 patients from 9 trials 39, 43, 45, [52] [53] [54] [55] [56] [57] (Table 4) , with an average stone size greater than 5 mm in all trials except 3. 39, 53, 55 Each study evaluated stones in the distal ureter; however, 3 studies included stones within the upper and middle ureteral tract. 52, 53, 57 
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Little heterogeneity existed in the group of calcium channel blocker studies. The Cochrane Q statistic ( 2 ϭ6.73) was not significant (Pϭ.566), there was minimal between study variance ( 2 ϭ0.000), and the I 2 statistic was 0% (95% CI 0% to 65%).
The combined results of all trials using a calcium channel blocker suggest that a benefit in stone expulsion is achieved when combined with standard therapy (RR 1.50; 95% CI 1.34 to 1.68) (Figure 4) . The number needed to treat is 3.9 (95% CI 3.2 to 4.6). Visual inspection of the funnel plot demonstrated mild asymmetry ( Figure 5 ). There was no evidence for publication bias when data were analyzed by Begg's test (Pϭ.35) or Egger's test (t for biasϭ1.1, Pϭ.31).
All 9 calcium channel blocker trials evaluated time to stone expulsion (Table 4) . When compared to standard therapy, a reduction in time to stone expulsion was observed in 7 of these trials. The mean time to stone expulsion in the treatment group, including the upper limit of the 95% CI, was less than 28 days in these trials.
Adverse effects were not consistently reported for all the trials. Overall, adverse effects were observed in 15.2% of patients in these trials. Mild adverse effects included nausea/vomiting (nϭ11), asthenia (nϭ10), dyspepsia (nϭ6), headache (nϭ3), drowsiness (nϭ4), euphoria (nϭ2), and not reported (nϭ3). Transient hypotension, not requiring discontinuation of therapy, occurred in 3 patients. A total of 10 patients discontinued therapy (2.9%). Of these patients, 4 experienced hypotension or palpitations and 6 experienced erythema or edema. The mean decrease in systolic blood pressure was 15 mm Hg (range 10 to 25 mm Hg), mean decrease in diastolic blood pressure was 8 mm Hg, and the mean increase in pulse rate was 8 beats/min.
52,54
Sensitivity and Subgroup Analysis
Our sensitivity analysis of ␣-antagonist and calcium channel blocker trials focused on the impact of poor-quality studies (ie, Jadad score Ͻ3) on the overall RR. A pooled analysis of 386 patients in 5 ␣-antagonist trials, 38, 39, 41, 43, 47 whose Jadad score was greater than or equal to 3, resulted in an RR of 1.66 (95% CI 1.45 to 1.89). Similarly, a pooled analysis of 380 patients in 4 calcium channel blocker trials, 39,43,52,54 whose Jadad score was greater than or equal to 3, resulted in an RR of 1.60 (95% CI 1.28 to 2.01).
Sequential exclusion of each study from the analysis of ␣-antagonist trials resulted in minor changes in the pooled RR or precision of the effect estimates, including exclusion of the study with the most influence, Avdoshin et al, 42 which resulted in an RR of 1.54 (95% CI 1.42 to 1.68). Elimination of this study from the pooled analysis reduced the summary I 2 statistic for ␣-antagonist studies to 5%. Identically, sequential exclusion of each study from the analysis of calcium channel blocker trials resulted in minimal changes in the pooled RR or precision. Elimination of the study with the most influence, Porpiglia et al, 54 resulted in an RR of 1.45 (95% CI 1.29 to 1.63). 
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Our subgroup analysis of the use of ␣-antagonists and calcium channel blockers focused on the impact of several potentially confounding medications (ie, anticholinergic agents, low-dose steroids, antibiotics) and the use of an ␣-antagonist besides tamsulosin on the overall summary RR (Table 5 and  Table 6 ). Minor changes to the overall relative risk were noted when these groups were analyzed independently.
LIMITATIONS
Up to one third of meta-analyses purporting successful therapy are later discredited after a large-scale, well-done, randomized, controlled trial is completed. 58 Thus, the results of using the meta-analysis study methodology to address a clinical question must be interpreted with caution. An advantage of the meta-analyses is to combine underpowered studies to increase the sample size and confidence of the results. However, aggregate results incorporate the biases of individual trials and evoke new sources of bias because of study selection and heterogeneity.
We anticipated some degree of heterogeneity when combining trials that were both clinically and methodologically diverse. Using the I 2 statistic, we identified a mild to moderate amount of across-study variance caused by heterogeneity in the trials that evaluated ␣-antagonists. Elimination of a single study 42 from the analysis significantly reduced this concern and had a diminutive effect on the overall RR. In this study, the rate of stone expulsion in the control group was significantly less than that reported in other studies, resulting in, perhaps, an artificially increased RR. The median Jadad score of 2 for all trials reflected the poor overall quality of studies reviewed. The absence of using a double-blinded methodology in the majority of trials reviewed and the lack of appropriate randomization in several trials limit the strength of our conclusions. Additionally, given the small numbers of patients enrolled in these studies, the inability to adjust for differences in factors beyond the reported baseline characteristics could have influenced the outcome reported within this study.
Although we attempted to limit bias by using an extensive search strategy, our results are limited by publication bias, which may lead to overestimation of treatment effect. In our analysis the ␣-antagonist and calcium channel blocker funnel plots demonstrated some amount of asymmetry by visual inspection, indicating potential publication bias. However, funnel plot asymmetry is also observed with conditions other than publication bias and can be seen, as is demonstrated by our data, when smaller studies within a meta-analysis demonstrate larger treatment effects. 59, 60 The results from Begg's test and Egger's test indicated a lack of publication bias in trials using calcium channel blockers but demonstrated evidence of publication bias in trials evaluating ␣-antagonists. We were unable to identify any article or scientific abstract data suggesting negative or neutral results with the use of ␣-antagonists. A contemporary move by major medical journals requiring authors to preregister randomized trials as a prerequisite for publication is anticipated to reduce the amount of publication bias in future meta-analyses.
The location of patient enrollment and follow-up time potentially hinder the application of these results to the ED. Indeed, a majority of trials included patients referred to a urologist, presumably after a previous evaluation by an emergency or primary care physician. Compared to patients who do not keep their urology appointment, patients who keep their appointment may reflect a subgroup less likely to experience spontaneous stone expulsion. However, there are no trials supporting the concept that the stone expulsion rate is different between patients evaluated in the ED and those evaluated at urologic follow-up. Furthermore, the majority of ureteral stones evaluated in these studies were greater than 5 mm, which is a group that is expected to have poor stone expulsion rates regardless of the site of patient enrollment.
DISCUSSION
The results of this meta-analysis suggest a significant benefit in the stone expulsion rate when either an ␣-antagonist or calcium channel blocker is added to standard therapy in the medical management of moderately sized distal ureteral stones. During a period of watchful waiting, patients may experience complications such as repeated renal colic, urinary infection, and hydronephrosis, all of which may prompt repeated evaluation. Alternatively, early endoscopic treatment with ureteroscopy or extracorporeal shockwave lithotripsy greatly improves stone passage rates. These procedures, however, are not risk free, [61] [62] [63] [64] [65] [66] [67] [68] require referral for urologic expertise, and are more costly than the watchful waiting approach. 69 Previous clinical reports describing the use of these agents in ureteral colic have focused on nifedipine for the treatment of pain. [70] [71] [72] [73] [74] [75] [76] [77] Our analysis focuses on trials that have evaluated the role of medical expulsive therapy in facilitating stone expulsion. Our results mirror those of a previous meta-analysis 78 and several nonsystematic reviews on the same subject. [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] Compared to a previous meta-analysis, our database included 7 additional ␣-antagonist trials 41, 42, [47] [48] [49] [50] [51] and 1 additional calcium channel blocker trial. 57 Additionally, our results are stratified by type of medication used, as opposed to combining ␣-antagonist and calcium channel blocker therapy. The summary RR obtained for medical expulsive therapy between our study and the previous meta-analyses is similar.
The results of this analysis demonstrate significant benefit when adjusted for the presence of confounding interventions (eg, anticholinergics, low-dose steroids, antibiotics) and elimination of lower-quality trials (Jadad score Ͻ3). Additionally, the overall time to stone expulsion was improved with the addition of either medication. However, several unanswered questions about ureteral stone size, stone location, concurrent use of adjunctive medication, and use of an ␣-antagonist other than tamsulosin deserve further consideration.
Small, less than 5-mm distal ureteral stones, will most likely spontaneously pass within 4 weeks, without the need for urologic intervention. [4] [5] [6] [7] [8] [9] [10] Separate analysis of 2 studies with tamsulosin 38, 48 and analysis of 3 studies with nifedipine 39, 52, 53 for stones up to 5 mm suggest some improvement in the stone expulsion rate and time to expulsion with the addition of either agent. However, the small number of patients in these studies does not allow any definitive conclusion about cost-to-benefit analysis in these patients. To our knowledge, there are no trials on medical expulsive therapy that specifically address large, greater than 10-mm ureteral stones in the absence of shockwave lithotripsy. The results of trials on medical expulsive therapy in patients concomitantly treated with shockwave lithotripsy suggest benefit of nifedipine 30, 31 and tamsulosin [31] [32] [33] [34] [35] 38 in this setting. A single study 89 and subgroup analysis of another study 51 have directly evaluated the role of steroids without adjunctive medication to facilitate ureteral stone expulsion, with mixed results. The addition of a low-dose steroid is thought to prevent edema around the ureteral stone and slowing of stone passage. The results of 2 trials comparing stone passage rates in patients receiving tamsulosin plus low-dose steroid to tamsulosin alone were mixed. 29, 51 Given the inconsistency of these results, no firm conclusion about the efficacy of adding low-dose steroids to medical expulsive therapy can be made.
Prophylactic antibiotics were commonly used in these studies to prevent urinary tract infection from developing and slowing stone passage. Separate analysis of steroid trials that also included the addition of an antibiotic suggests marginal benefit when either of these agents is added to tamsulosin.
The most commonly used agent was tamsulosin 0.4 mg taken daily for 1 month; however, in several trials, terazosin (5 to 10 mg daily by mouth) 40, 46, 50 and doxazosin (4 mg daily by mouth) 46, 49 were used with similar efficacy. The success of these trials and of uncontrolled trials with doxazosin 26 and alfuzosin 27, 28 suggests that the benefit of ␣-antagonists may be a class effect and not specific to tamsulosin. To our knowledge, no other calcium channel blocker has published data validating its use for medical expulsive therapy, although experimental data with diltiazem and verapamil suggest that these agents may also be helpful. 13, 14 We found no trials evaluating the combination of ␣-antagonist to calcium channel blocker to facilitate stone passage. Furthermore, no data exist on the addition of either therapy when combined with ␤-adrenergic antagonists 90 or glyceryl trinitrate.
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A 1-month follow-up period was selected by the majority of authors according to current urologic practice and recommendations. 11 During this time, the use of an ␣-antagonist was associated with a 2-to 6-day reduction in time to stone expulsion. Similarly, the majority of trials evaluating calcium channel blockers reported an improvement in time to stone expulsion. The mean time to successful stone expulsion, including upper limit of the 95% CI, was fewer than 14 days in the ␣-antagonist trials and fewer than 28 days in the calcium channel-blocker trials, suggesting that a 2-to 4-week time course of these medications is warranted.
Both ␣-antagonists and calcium channel blockers are well tolerated, with minimal adverse effects. Overall, 4% of patients receiving ␣-antagonist and 15.2% of patients receiving calcium channel-blocker therapy experienced adverse effects. Only 1 patient (0.2%) required discontinuation of ␣-antagonist therapy during treatment, and 10 patients (2.9%) required discontinuation of calcium channel blocker therapy. No reports of impotence, ejaculatory failure, or decreased libido were reported with the short-course administration of an ␣-antagonist.
The results of this meta-analysis are encouraging for the use of an ␣-antagonist or calcium channel blocker to facilitate stone expulsion of moderately sized distal ureteral calculi; however, because of the limitations of methodologic quality within the studies reviewed, a large, well-done, randomized, clinical trial is needed to confirm these results before uniform adoption can be recommended. 
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